BRPI0511952A - receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 - Google Patents
receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14Info
- Publication number
- BRPI0511952A BRPI0511952A BRPI0511952-9A BRPI0511952A BRPI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A
- Authority
- BR
- Brazil
- Prior art keywords
- induced
- antibody
- reducing
- methods
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
RECEPTOR SOLUVEL ISOLADO, ANTICORPO OU FRAGMENTO DE ANTICORPO, E, MéTODOS DE REDUZIR INFLAMAçãO INDUZIDA POR IL-17A OU INDUZIDA POR IL-17F, DE TRATAR UM MAMìFERO AFETADO COM UMA DOENçA INFLAMATóRIA, E UMA CONDIçãO PATOLóGICA EM UM INDIVìDUO ASSOCIADA COM ATIVIDADE DE ZCYTORl4 presente invenção refere-se ao bloqueio, inibição, redução, antagonização ou neutralização da atividade de moléculas de polipeptídeo IL-l7F, IL-17A, ou tanto IL-17A como IL-17F. IL-17A e IL-17F são citocinas que estão envolvidas em processos inflamatórios e doença humana. ZcytoRl4 é um receptor comum para IL- 1 7A e IL- 1 7F. A presente invenção inclui ZcytoRl4 solúvel, anticorpos anti-ZcytoRl4, e parceiros de ligação, assim como métodos para antagonizar IL- 1 7F, IL- 1 7A, ou tanto IL- 1 7A como IL-17F, usando estes receptores solúveis, anticorpos e parceiros de ligação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57880504P | 2004-06-10 | 2004-06-10 | |
PCT/US2005/020521 WO2005123778A2 (en) | 2004-06-10 | 2005-06-10 | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511952A true BRPI0511952A (pt) | 2008-01-29 |
Family
ID=35407029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511952-9A BRPI0511952A (pt) | 2004-06-10 | 2005-06-10 | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 |
Country Status (11)
Country | Link |
---|---|
US (4) | US7910540B2 (pt) |
EP (1) | EP1765865A2 (pt) |
JP (1) | JP4903703B2 (pt) |
CN (1) | CN101001871A (pt) |
AU (1) | AU2005254998B2 (pt) |
BR (1) | BRPI0511952A (pt) |
CA (1) | CA2569867A1 (pt) |
IL (2) | IL179356A (pt) |
MX (1) | MXPA06014465A (pt) |
NO (1) | NO20070153L (pt) |
WO (1) | WO2005123778A2 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US7324615B2 (en) * | 2003-12-15 | 2008-01-29 | Microchip Technology Incorporated | Time signal receiver and decoder |
US7910540B2 (en) * | 2004-06-10 | 2011-03-22 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
BRPI0608210A2 (pt) | 2005-02-14 | 2010-11-09 | Wyeth Corp | métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina |
AU2006214473A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
AU2006294511B2 (en) | 2005-09-28 | 2011-11-17 | Zymogenetics, Inc | IL-17A and IL-17F antagonists and methods of using the same |
CA2638864A1 (en) * | 2006-02-10 | 2007-10-18 | Zymogenetics, Inc. | Truncated il-17ra soluble receptor and methods of using in inflammation |
WO2008039553A1 (en) * | 2006-02-10 | 2008-04-03 | Zymogenetics, Inc. | Soluble il-17rcx4 and methods of using in inflammation |
US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
CA2646478A1 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
US9101670B2 (en) | 2006-04-07 | 2015-08-11 | Nektar Therapeutics | Conjugates of an anti-TNF-α antibody |
GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
CN101679497A (zh) | 2007-03-26 | 2010-03-24 | 津莫吉尼蒂克斯公司 | 可溶性il-17ra/rc融合蛋白以及相关方法 |
CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
AU2008242665B2 (en) * | 2007-04-20 | 2013-09-05 | Amgen Inc. | Identification and method for using the Pre-Ligand Assembly Domain of the IL-17 receptor |
WO2008133684A1 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
EP2170958A1 (en) * | 2007-06-13 | 2010-04-07 | Amgen Inc. | Il-17 heteromeric receptor complex |
US20100239590A1 (en) * | 2007-06-20 | 2010-09-23 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
ES2614735T3 (es) * | 2007-07-23 | 2017-06-01 | Janssen Biotech, Inc. | Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17 |
WO2009026412A1 (en) * | 2007-08-21 | 2009-02-26 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
EP2203476B1 (en) | 2007-09-25 | 2016-10-26 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
US9309313B2 (en) | 2008-01-09 | 2016-04-12 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
WO2009136286A2 (en) | 2008-05-05 | 2009-11-12 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
WO2011096438A1 (ja) * | 2010-02-03 | 2011-08-11 | 国立大学法人 東京大学 | 腸疾患の治療方法及び治療用医薬組成物 |
CN102188707B (zh) * | 2011-02-25 | 2015-08-05 | 中国医学科学院基础医学研究所 | Il-17抑制剂在制备治疗流感的药物中的用途 |
WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
US9708401B2 (en) | 2012-05-22 | 2017-07-18 | Bristol-Myers Squibb Company | IL-17A/F cross-reactive monoclonal antibodies and methods of using the same |
KR20220004134A (ko) * | 2019-04-26 | 2022-01-11 | 프로린크스 엘엘시 | 서방형 사이토카인 컨쥬게이트 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5684032A (en) * | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
JP4373495B2 (ja) | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Il−17受容体 |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US20030100051A1 (en) | 1998-05-12 | 2003-05-29 | Ruben Steven M. | 97 human secreted proteins |
US6579520B2 (en) * | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US20020177188A1 (en) * | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6569645B2 (en) * | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
WO1998049307A1 (en) | 1997-05-01 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like receptor |
US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
US6635443B1 (en) | 1997-09-17 | 2003-10-21 | Human Genome Sciences, Inc. | Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein |
US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
US20030040471A1 (en) | 1998-04-29 | 2003-02-27 | Watson James D. | Compositions isolated from skin cells and methods for their use |
US7247442B1 (en) | 1998-05-12 | 2007-07-24 | Human Genome Sciences, Inc. | Antibodies to HHPEN62 polypeptide |
CA2332109A1 (en) | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
JP3577586B2 (ja) | 1998-05-15 | 2004-10-13 | ジェネンテック・インコーポレーテッド | Il−17相同的ポリペプチドとその治療用途 |
US20020182673A1 (en) | 1998-05-15 | 2002-12-05 | Genentech, Inc. | IL-17 homologous polypedies and therapeutic uses thereof |
US20030166132A1 (en) | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7507404B2 (en) | 1999-03-08 | 2009-03-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
ES2364086T3 (es) * | 1999-07-07 | 2011-08-24 | Zymogenetics, Inc. | Receptor de citoquina humana. |
ATE519847T1 (de) | 1999-12-23 | 2011-08-15 | Genentech Inc | Il-17-homologe polypeptide und ihre therapeutische verwendung |
US20040048249A1 (en) | 2000-01-21 | 2004-03-11 | Tang Y. Tom | Novel nucleic acids and secreted polypeptides |
EP1268773A1 (en) | 2000-03-08 | 2003-01-02 | Human Genome Sciences, Inc. | Immune system-related polynucleotides, polypeptides, and antibodies |
JP2003534013A (ja) * | 2000-05-24 | 2003-11-18 | シェーリング コーポレイション | 哺乳動物レセプタータンパク質;関連試薬および方法 |
AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
US20040197306A1 (en) | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
US20020146763A1 (en) | 2000-07-06 | 2002-10-10 | Zeren Gao | Murine cytokine receptor |
WO2002038764A2 (en) | 2000-11-10 | 2002-05-16 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
US6681210B2 (en) | 2001-09-04 | 2004-01-20 | Andrew Jeffrey Kelly | Modular service payroll system |
US20040097447A1 (en) * | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of interleukin 22 receptor expression |
EP1641822B1 (en) | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
US7910540B2 (en) | 2004-06-10 | 2011-03-22 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
AU2006214473A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
AU2006294511B2 (en) | 2005-09-28 | 2011-11-17 | Zymogenetics, Inc | IL-17A and IL-17F antagonists and methods of using the same |
WO2008039553A1 (en) | 2006-02-10 | 2008-04-03 | Zymogenetics, Inc. | Soluble il-17rcx4 and methods of using in inflammation |
CN101679497A (zh) | 2007-03-26 | 2010-03-24 | 津莫吉尼蒂克斯公司 | 可溶性il-17ra/rc融合蛋白以及相关方法 |
-
2005
- 2005-06-10 US US11/150,533 patent/US7910540B2/en active Active
- 2005-06-10 WO PCT/US2005/020521 patent/WO2005123778A2/en active Application Filing
- 2005-06-10 EP EP05785507A patent/EP1765865A2/en not_active Withdrawn
- 2005-06-10 CN CNA2005800271040A patent/CN101001871A/zh active Pending
- 2005-06-10 JP JP2007527770A patent/JP4903703B2/ja not_active Expired - Fee Related
- 2005-06-10 AU AU2005254998A patent/AU2005254998B2/en not_active Ceased
- 2005-06-10 BR BRPI0511952-9A patent/BRPI0511952A/pt not_active IP Right Cessation
- 2005-06-10 CA CA002569867A patent/CA2569867A1/en not_active Abandoned
- 2005-06-10 MX MXPA06014465A patent/MXPA06014465A/es active IP Right Grant
-
2006
- 2006-10-04 US US11/538,574 patent/US20070048826A1/en not_active Abandoned
- 2006-10-04 US US11/538,579 patent/US20070048257A1/en not_active Abandoned
- 2006-11-16 IL IL179356A patent/IL179356A/en not_active IP Right Cessation
-
2007
- 2007-01-09 NO NO20070153A patent/NO20070153L/no not_active Application Discontinuation
-
2010
- 2010-10-21 IL IL208859A patent/IL208859A/en not_active IP Right Cessation
-
2011
- 2011-01-27 US US13/015,304 patent/US8268773B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP4903703B2 (ja) | 2012-03-28 |
US20070048257A1 (en) | 2007-03-01 |
US20110177083A1 (en) | 2011-07-21 |
CN101001871A (zh) | 2007-07-18 |
NO20070153L (no) | 2007-03-09 |
EP1765865A2 (en) | 2007-03-28 |
MXPA06014465A (es) | 2007-05-16 |
IL179356A (en) | 2011-07-31 |
IL208859A0 (en) | 2011-01-31 |
JP2008509227A (ja) | 2008-03-27 |
WO2005123778A2 (en) | 2005-12-29 |
IL179356A0 (en) | 2007-03-08 |
WO2005123778A3 (en) | 2006-02-09 |
CA2569867A1 (en) | 2005-12-29 |
US7910540B2 (en) | 2011-03-22 |
IL208859A (en) | 2013-01-31 |
US8268773B2 (en) | 2012-09-18 |
US20070048826A1 (en) | 2007-03-01 |
AU2005254998B2 (en) | 2011-10-27 |
US20060002925A1 (en) | 2006-01-05 |
AU2005254998A1 (en) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511952A (pt) | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 | |
BRPI0408705A (pt) | método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20 | |
CY1117702T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη | |
IL192950A0 (en) | Soluble il-17rcx4 and methods of using in inflammation | |
IL182503A0 (en) | Anti-il-22ra antibodies and binding partners and methods of using in inflammation | |
NO20090224L (no) | Anti-IL-6 monoklonale antistoffer og anvendelser derav | |
WO2007106769A3 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
Lin et al. | Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells | |
BRPI0406689A (pt) | Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório | |
WO2008133684A8 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
WO2006086396A3 (en) | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation | |
BRPI0812913B8 (pt) | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos | |
RU2008126932A (ru) | Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами | |
MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
WO2009082624A3 (en) | Antagonists of il-17a, il-17f, and il-23 and methods of using the same | |
AR059604A1 (es) | Anticuerpos contra il- 22 humana y usos para los mismos | |
NO20056236L (no) | Behandling med anti-VEGF-antistoffer | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
BRPI0716088B8 (pt) | anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit | |
BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
BRPI0519775A2 (pt) | proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica | |
ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
BR112023001942A2 (pt) | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento | |
EA200700823A1 (ru) | Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014. |